Podcasts about rory collins

Audio FileGround Truths can also be found on Apple Podcasts, Spotify and YouTube.The UK is the world leader in human genomics, and laid the foundation for advancing medicine with the UK Biobank, Genomes England and now Our Future Health (w/ 5 million participants). Sir John Bell is a major force in driving and advising these and many other initiatives. After 22 years as the Regius Professor of Medicine at the University of Oxford he left in 2024 to be President of the Ellison Institute of Technology. Professor Bell has been duly recognized in the UK: knighted in 2015 and appointed Companion of Honor in 2023. In our conversation, you will get a sense for how EIT will be transformational for using A.I. and life science for promoting human health.Transcript with audio links Eric Topol (00:06):Hello, this is Eric Topol from Ground Truths. And I'm really delighted to welcome today, Sir John Bell who had an extraordinary career as a geneticist, immunologist, we'll talk about several initiatives he's been involved with during his long tenure at University of Oxford, recently became head of the Ellison Institute of Technology (EIT) in the UK. So welcome, John.Sir John Bell (00:30):Thanks, Eric. Thanks very much for having me.Eric Topol (00:34):Well, I think it's just extraordinary the contributions that you have made and continue to make to advance medicine, and I thought what we could do is get into that. I mean, what's interesting, you have had some notable migrations over your career, I think starting in Canada, at Stanford, then over as Rhodes Scholar in Oxford. And then you of course had a couple of decades in a very prestigious position, which as I understand was started in 1546 by King Henry VII, and served as the Regius Professor of Medicine at the University of Oxford. Do I have that right?Sir John Bell (01:11):It was actually Henry VIII, but you were close.Eric Topol (01:14):Henry VIII, that's great. Yeah. Okay, good. Well, that's a pretty notable professorship. And then of course in recent times you left to head up this pretty formidable new institute, which is something that's a big trend going on around the world, particularly in the US and we'll talk about. So maybe we can start with the new thing. Tell us more about the Ellison Institute of Technology (EIT), if you will.Sir John Bell (01:47):Yeah. So as you know, Larry Ellison has been one of the great tech entrepreneurs focused really on developing terrific databases over his career and through Oracle, which is the company that he founded. And Larry is really keen to try and give back something substantial to the world, which is based on science and technology. So he and I did quite a bit together over the Covid pandemic. He and I talked a lot about what we're doing and so on. He came to visit afterwards and he had, I think he decided that the right way to make his contributions would be to set up an institute that would be using the state-of-the-art science and technology with a lot of AI and machine learning, but also some of the other modern tools to address the major problems in healthcare, in food security, in green energy and climate change and in global governance.Sir John Bell (02:49):So anyway, he launched this about 18 months ago. He approached me to ask whether I would run it. He wanted to set it up outside Oxford, and he wanted to do something which is a bit different than others. And that is his view was that we needed to try and create solutions to these problems which are commercially viable and not all the solutions are going to be commercially viable, but where you can create those, you make them sustainable. So the idea is to make sure that we create solutions that people want to buy, and then if they buy them, you can create a sustainable solution to those issues. So we are actually a company, but we are addressing many of the same problems that the big foundations are addressing. And the big issues that you and I talk about in health, for example, are all on our list. So we're kind of optimistic as to where this will go and Larry's supporting the project and we're going to build out an institute here which will have about 5,000 people in it, and we'll be, I think a pretty exciting new addition to the science and technology ecosystem globally.Eric Topol (04:02):Well, I know the reverberations and the excitement is palpable and some of the colleagues I've spoken to, not just in England, but of course all over the world. So congratulations on that. It was a big move for you to leave the hardcore academics. And the other thing I wanted to ask you, John, is you had distinguished your career in immunology, in genetics, type 1 diabetes and other conditions, autoimmune conditions, and now you've really diversified, as you described with these different areas of emphasis at the new institute. Is that more fun to do it or do you have deputies that you can assign to things like climate change in other areas?Sir John Bell (04:50):Trust me, Eric, I'm not making any definitive decisions about areas I know nothing about, but part of this is about how do you set up leadership, run a team, get the right people in. And I have to say one of the really interesting things about the institute is we've been able to recruit some outstanding people across all those domains. And as you know, success is almost all dependent on people. So we're really pretty optimistic we're going to have a significant impact. And of course, we also want to take risks because not a lot of point in us doing stuff that everybody else is doing. So we're going to be doing some things that are pretty way out there and some of them will fail, so we are just going to get used to trying to make sure we get a few of them across the finish line. But the other thing is that, and you've experienced this too, you never get too old to learn. I mean, I'm sucking up stuff that I never thought I would ever learn about, which is fun actually, and really marvel.Eric Topol (05:55):It's fantastic. I mean, you've really broadened and it's great that you have the runway to get these people on board and I think you're having a big building that's under construction?Sir John Bell (06:07):Yeah, we've got the original building that Larry committed to is about 330,000 square feet of space. I mean, this is completely amazing, but we are of course to accommodate up to 5,000 people, we're going to need more than that. So we are looking at a much wider campus here that'll involve more than just that building. I think we'll end up with several million square feet of space by the time we're finished. So mean, it's a really big project, but we've already made progress in some domains to try and get projects and the beginnings of companies on the road to try and solve some of the big problems. So we're quite excited about it.Eric Topol (06:49):Now you, I assume it's pretty close to Oxford, and will you have some kind of inter interactions that are substantial?Sir John Bell (06:58):Yeah, so the university's been terrific about this actually, because of course most universities would say, well, why don't you do it inside the university and just give us the money and it'll all be fine. So of course Larry. Larry wasn't born yesterday, so I said, well, thank you very much, but I think we'll probably do this nearby. But the university also realized this is a really exciting opportunity for them and we've got a really good relationship with them. We've signed an agreement with them as to who will work where. We've agreed not to steal a lot of their staff. We're going to be bringing new people into the ecosystem. Some of the university people will spend some time with us and sometime in the university, so that will help. But we're also bringing quite a few new people into the setting. So the university has been really positive. And I think one of the things that's attractive to the university, and you'll be familiar with this problem in the UK, is that we're quite good. The discovery science here is pretty good.Sir John Bell (08:06):And we do startups now at scale. So Oxford does lots of little startup companies in the biotech space and all the rest of it, but we never scale any of these companies because there isn't the depth of capital for scaling capital to get these things scaled. And so, in a way what we're trying to do here at Ellison actually avoids that problem because Larry knows how to scale companies, and we've got the financial support now. If we have things that are really successful, we can build the full stack solution to some of these problems. So I think the university is really intrigued as to how we might do that. We're going to have to bring some people in that know how to do that and build billion dollar companies, but it's sufficiently attractive. We've already started to recruit some really outstanding people. So as a way to change the UK system broadly, it's actually quite a good disruptive influence on the way the thing works to try and fix some of the fundamental problems.Eric Topol (09:07):I love that model and the ability that you can go from small startups to really transformative companies have any impact. It fits in well with the overall objectives, I can see that. The thing that also is intriguing regarding this whole effort is that in parallel we've learned your influence. The UK is a genomics world leader without any question and no coincidence that that's been your area of emphasis in your career. So we've watched these three initiatives that I think you were involved in the UK Biobank, which has had more impact than any cohort ever assembled. Every day there's another paper using that data that's coming out. There's Genomes England, and then now Our Future Health, which a lot of people don't know about here, which is well into the 5 million people enrollment. Can you tell us about, this is now 15 years ago plus when these were started, and of course now with a new one that's the biggest ever. What was your thinking and involvement and how you built the UK to be a world leader in this space?Sir John Bell (10:26):So if you turn the clock back 20 years, or actually slightly more than 25 years ago, it was clear that genomics was going to have a play. And I think many of us believed that there was going to be a genetic element to most of the major common disease turn out to be true. But at the time, there were a few skeptics, but it seemed to us that there was going to be a genetic story that underpinned an awful lot of human disease and medicine. And we were fortunate because in Oxford as you know, one of my predecessors in the Regius job was Richard Doll, and he built up this fantastic epidemiology capability in Oxford around Richard Peto, Rory Collins, and those folks, and they really knew how to do large scale epidemiology. And one of the things that they'd observed, which is it turns out to be true with genetics as well, is a lot of the effects are relatively small, but they're still quite significant. So you do need large scale cohorts to understand what you're doing. And it was really Richard that pioneered the whole thinking behind that. So when we had another element in the formula, which was the ability to detect genetic variation and put that into the formula, it seemed to me that we could move into an era where you could set up, again, large cohorts, but build into the ability to have DNA, interrogate the DNA, and also ultimately interrogate things like proteomics and metabolomics, which were just in their infancy at that stage.Sir John Bell (12:04):Very early on I got together because I was at that stage at the Nuffield Chair of Medicine, and I got together, Rory and Richard and a couple of others, and we talked a little bit about what it would look like, and we agreed that a half a million people late to middle age, 45 and above would probably over time when you did the power calculations, give you a pretty good insight in most of the major diseases. And then it was really a question of collecting them and storing the samples. So in order to get it funded at the time I was on the council of the MRC and George Radda, who you may remember, was quite a distinguished NMR physiologist here. He was the chief executive of the MRC. So I approached him and I said, look, George, this would be a great thing for us to do in the UK because we have all the clinical records of these people going back for a decade, and will continue to do that.Sir John Bell (13:01):Of course, we immediately sent it out to a peer review committee in the MRC who completely trashed the idea and said, you got to be joking. So I thought, okay, that's how that lasted. And I did say to George, I said, that must mean this is a really good idea because if it had gone straight through peer review, you would've known you were toast. So anyway, I think we had one more swing at peer review and decided in the end that wasn't going to work. In the end, George to his credit, took it to MRC council and we pitched it and everybody thought, what a great idea, let's just get on and do it. And then the Wellcome came in. Mark Walport was at the Wellcome at the time, great guy, and did a really good job at bringing the Wellcome on board.Sir John Bell (13:45):And people forget the quantum of money we had to do this at the time was about 60 million pounds. I mean, it wasn't astonishly small. And then of course we had a couple of wise people who came in to give us advice, and the first thing they said, well, if you ever thought you were really going to be able to do genetics on 500,000 people, forget it. That'll never work. So I thought, okay, I'll just mark that one out. And then they said, and by the way, you shouldn't assume you can get any data from the health service because you'll never be able to collect clinical data on any of these people. So I said, yeah, yeah, okay, I get it. Just give us the money and let us get on. So anyway, it's quite an interesting story. It does show how conservative the community actually is for new ideas.Sir John Bell (14:39):Then I chaired the first science committee, and we decided about a year into it that we really needed the chief executive. So we got Rory Collins to lead it and done it. I sat on the board then for the next 10 years, but well look, it was a great success. And as you say, it is kind of the paradigm for now, large genetic epidemiology cohorts. So then, as you know, I advise government for many years, and David Cameron had just been elected as Prime Minister. This was in about 2010. And at the time I'd been tracking because we had quite a strong genomics program in the Wellcome Trust center, which I'd set up in the university, and we were really interested in the genetics of common disease. It became clear that the price of sequencing and Illumina was now the clear leader in the sequencing space.Sir John Bell (15:39):But it was also clear that Illumina was making significant advances in the price of sequencing because as you remember, the days when it cost $5,000 to do a genome. Anyway, it became clear that they actually had technology that gets you down to a much more sensible price, something like $500 a genome. So I approached David and I said, we are now pretty sure that for many of the rare diseases that you see in clinical practice, there is a genetic answer that can be detected if you sequenced a whole genome. So why don't we set something up in the NHS to provide what was essentially the beginnings of a clinical service to help the parents of kids with various disabilities work out what's going on, what's wrong with their children. And David had had a child with Ohtahara syndrome, which as you know is again, and so David was very, he said, oh God, I'll tell you the story about how awful it was for me and for my wife Samantha.Sir John Bell (16:41):And nobody could tell us anything about what was going on, and we weren't looking for a cure, but it would've really helped if somebody said, we know what it is, we know what the cause is, we'll chip away and maybe there will be something we can do, but at least you know the answer. So anyway, he gave us very strong support and said to the NHS, can you please get on and do it? Again massive resistance, Eric as you can imagine, all the clinical geneticists said, oh my God, what are they doing? It's complete disaster, dah, dah, dah. So anyway, we put on our tin hats and went out and got the thing going. And again, they did a really good job. They got to, their idea was to get a hundred thousand genomes done in a reasonable timeframe. I think five years we set ourselves and the technology advance, people often underestimate the parallel development of technology, which is always going on. And so, that really enabled us to get that done, and it still continues. They're doing a big neonatal program at the moment, which is really exciting. And then I was asked by Theresa May to build a life science strategy because the UK, we do this stuff not as big and broad as America, but for a small country we do life sciences pretty well.Eric Topol (18:02):That's an understatement, by the way. A big understatement.Sir John Bell (18:04):Anyway, so I wrote the strategies in 2017 for Theresa about what we would do as a nation to support life sciences. And it was interesting because I brought a group of pharma companies together to say, look, this is for you guys, so tell us what you want done. We had a series of meetings and what became clear is that they were really interested in where healthcare was going to end up in the next 20 years. And they said, you guys should try and get ahead of that wave. And so, we agreed that one of the domains that really hadn't been explored properly, it was the whole concept of prevention.Sir John Bell (18:45):Early diagnosis and prevention, which they were smart enough to realize that the kind of current paradigm of treating everybody in the last six months of life, you can make money doing that, there's no doubt, but it doesn't really fix the problem. And so, they said, look, we would love it if you created a cohort from the age of 18 that was big enough that we could actually track the trajectories of people with these diseases, identify them at a presymptomatic stage, intervene with preventative therapies, diagnose diseases earlier, and see if we could fundamentally change the whole approach to public health. So we anyway, went back and did the numbers because of course at much wider age group, a lot of people don't get at all sick, but we thought if we collected 5 million people, we would probably have enough. That's 10% of the UK adult population.Sir John Bell (19:37):So anyway, amazingly the government said, off you go. We then had Covid, which as you know, kept you and I busy for a few years before we could get back to it. But then we got at it, and we hired a great guy who had done a bit of this in the UAE, and he came across and we set up a population health recruitment structure, which was community-based. And we rapidly started to recruit people. So we've now got 2.9 million people registered, 2.3 million people consented, and we've got blood in the bank and all the necessary data including questionnaire data for 1.5 million people growing up. So we will get to 5 million and it's amazing.Eric Topol (20:29):It is. It really is, and I'm just blown away by the progress you've made. And what was interesting too, besides you all weren't complacent about, oh, we got this UK Biobank and you just kept forging ahead. And by the way, I really share this importance of finally what has been a fantasy of primary prevention, which never really achieved. It's always, oh, after a heart attack. But that's what I wrote about in the Super Agers book, and I'll get you a copy.Sir John Bell (21:02):No, I know you're a passionate believer in this and we need to do a lot of things. So we need to work out what's the trial protocol for primary prevention. We need to get the regulators on board. We've got to get them to understand that we need diagnostics that define risk, not disease, because that's going to be a key bit of what we're going to try and do. And we need to understand that for a lot of these diseases, you have to intervene quite early to flatten that morbidity curve.Eric Topol (21:32):Yeah, absolutely. What we've learned, for example, from the UK Biobank is not just, of course the genomics that you touched on, but the proteomics, the organ clocks and all these other layers of data. So that gets me to my next topic, which I know you're all over it, which is AI.Eric Topol (21:51):So when I did the NHS review back in 2018, 2019, the group of people which were amazing that I had to work with no doubt why the UK punches well beyond its weight. I had about 50 people, and they just said, you know what? Yeah, we are the world leaders in genomics. We want to be the world leader in AI. Now these days you only hear about US and China, which is ridiculous. And you have perhaps one of the, I would say most formidable groups there with Demis and Google DeepMind, it's just extraordinary. So all the things that the main foci of the Ellison Institute intersect with AI.Sir John Bell (22:36):They do. And we, we've got two underpinning platforms, well actually three underpinning platforms that go across all those domains. Larry was really keen that we became a real leader in AI. So he's funded that with a massive compute capacity. And remember, most universities these days have a hard time competing on compute because it's expensive.Eric Topol (22:57):Oh yeah.Sir John Bell (22:58):So that is a real advantage to us. He's also funded a great team. We've recruited some people from Demis's shop who are obviously outstanding, but also others from around Europe. So we really, we've recruited now about 15 really outstanding machine learning and AI people. And of course, we're now thinking about the other asset that the UK has got, and particularly in the healthcare space is data. So we do have some really unique data sets because those are the three bits of this that you need if you're going to make this work. So we're pretty excited about that as an underpinning bit of the whole Ellison Institute strategy is to fundamentally underpin it with very strong AI. Then the second platform is generative biology or synthetic biology, because this is a field which is sort of, I hesitate to say limped along, but it's lacked a real focus.Sir John Bell (23:59):But we've been able to recruit Jason Chin from the LMB in Cambridge, and he is one of the real dramatic innovators in that space. And we see there's a real opportunity now to synthesize large bits of DNA, introduce them into cells, microbes, use it for a whole variety of different purposes, try and transform plants at a level that people haven't done before. So with AI and synthetic biology, we think we can feed all the main domains above us, and that's another exciting concept to what we're trying to do. But your report on AI was a bit of a turning point for the UK because you did point out to us that we did have a massive opportunity if we got our skates, and we do have talent, but you can't just do it with talent these days, you need compute, and you need data. So we're trying to assemble those things. So we think we'll be a big addition to that globally, hopefully.Eric Topol (25:00):Yeah. Well that's another reason why I am so excited to talk to you and know more about this Ellison Institute just because it's unique. I mean, there are other institutes as like Chan Zuckerberg, the Arc Institute. This is kind of a worldwide trend that we're seeing where great philanthropy investments are being seen outside of government, but none have the computing resources that are being made available nor the ability to recruit the AI scientists that'll help drive this forward. Now, the last topic I want to get into with you today is one that is where you're really grounded in, and that's the immune response.Eric Topol (25:43):So it's pretty darn clear now that, well, in medicine we have nothing. We have the white cell neutrophil to lymphocyte ratio, what a joke. And then on the other hand, we can do T and B cell sequencing repertoires, and we can do all this stuff, autoantibody screens, and the list goes on and on. How are we ever going to make a big dent in health where we know the immune system is such a vital part of this without the ability to check one's immune status at any point in time in a comprehensive way? What are your thoughts about that?Sir John Bell (26:21):Yeah, so you seem to be reading my mind there. We need to recruit you over here because I mean, this is exactly, this is one of our big projects that we've got that we're leaning into, and that is that, and we all experienced in Covid the ins and outs of vaccines, what works, what doesn't work. But what very clear is that we don't really know anything about vaccines. We basically, you put something together and you hope the trial works, you've got no intermediate steps. So we're building a really substantial immunophenotyping capability that will start to interrogate the different arms of the immune response at a molecular level so that we can use a combination of human challenge models. So we've got a big human challenge model facility here, use human challenge models with pathogens and with associated vaccines to try and interrogate which bits of the immune response are responsible for protection or therapy of particular immunologically mediated diseases or infectious diseases.Sir John Bell (27:30):And a crucial bit to that. And one of the reasons people have tried this before, but first of all, the depth at which you can interrogate the immune system has changed a lot recently, you can get a lot more data. But secondly, this is again, where the AI becomes important because it isn't going to be a simple, oh, it's the T-cell, it's going to be, well, it's a bit of the T cells, but it's also a bit of the innate immune response and don't forget mate cells and don't forget a bit of this and that. So we think that if we can assemble the right data set from these structured environments, we can start to predict and anticipate which type of immune response you need to stimulate both for therapy and for protection against disease. And hopefully that will actually create a whole scientific foundation for vaccine development, but also other kinds of immune therapy and things like cancer and potentially autoimmune disease as well. So that's a big push for us. We're just busy. The lab isn't set up. We've got somebody to run the lab now. We've got the human challenge model set up with Andy Pollard and colleagues. So we're building that out. And within six months, I think we'll be starting to collect data. So I'm just kind of hoping we can get the immune system in a bit more structured, because you're absolutely right. It's a bit pin the tail on the donkey at the moment. You have no idea what's actually causing what.Eric Topol (29:02):Yeah. Well, I didn't know about your efforts there, and I applaud that because it seems to me the big miss, the hole and the whole story about how we're going to advanced human health and with the recent breakthroughs in lupus and these various autoimmune diseases by just targeting CD19 B cells and resetting like a Ctrl-Alt-Delete of their immune system.Sir John Bell (29:27):No, it's amazing. And you wouldn't have predicted a lot of this stuff. I think that means that we haven't really got under the skin of the mechanistic events here, and we need to do more to try and get there, but there's steady advance in this field. So I'm pretty optimistic we'll make some headway in this space over the course of the next few years. So we're really excited about that. It's an important piece of the puzzle.Eric Topol (29:53):Yeah. Well, I am really impressed that you got all the bases covered here, and what a really exhilarating chance to kind of peek at what you're doing there. And we're going to be following it. I know I'm going to be following it very closely because I know all the other things that you've been involved with in your colleagues, big impact stuff. You don't take the little swings here. The last thing, maybe to get your comment, we're in a state of profound disruption here where science is getting gutted by a madman and his henchmen, whatever you want to call it, which is really obviously a very serious state. I'm hoping this is a short term hit, but worried that this will have a long, perhaps profound. Any words of encouragement that we're going to get through this from the other side of the pond?Sir John Bell (30:52):Well, I think regardless of the tariffs, the scientific community are a global community. And I think we need to remember that because our mission is a global mission, and we need to lean into that together. First of all, America is such a powerhouse of everything that's been done scientifically in the human health domain. But not only that, but across all the other domains that we work in, we can't really make the kind of progress that we need to without America being part of the agenda. So first of all, a lot of sympathy for you and your colleagues. I know it must be massively destabilizing for you, not be confident that the things that work are there to help you. But I'm pretty confident that this will settle down. Most of the science is for, well, all the science is really for public good, and I think the public recognizes it and they'll notice if it's not being prosecuted in the way that it has to be. And the global science community cannot survive without you. So we're all leaning in behind you, and I hope it will settle. One of my worries is that these things take years to set up and literally hours or minutes to destroy. So we can't afford to take years to set them back up again. So we do need to be a bit careful about that, but I still have huge confidence in what you guys can achieve and we're all behind you.Eric Topol (32:37):Well, that's really helpful getting some words of wisdom from you there, John. So this has been terrific. Thanks so much for joining, getting your perspective on what you're doing, what's important is so essential. And we'll stay tuned for sure.Sir John Bell (32:59):And come and visit us at the EIT, Eric. We'd be glad to see you.*******************************Some of the topics that John and I discussed—immunology, A.I., genomics, and prevention—are emphasized in my new book SUPER AGERS. A quick update: It will have a new cover after making the New York Times Bestseller list and is currently ranked #25 for all books on Amazon. Thanks to so many of you for supporting the book!Here are a few recent podcasts:Dax Shepard: Dr. Mike Sanjay Gupta ***********************Thanks for reading and subscribing to Ground Truths.If you found this interesting please share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths— newsletters, analyses, and podcasts—is free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

Brian Kiley has made over 20 appearances on legendary shows like The Late Show with David Letterman, The Tonight Show, and Late Night with Conan O'Brien. He spent more than two decades as a staff writer for Conan, eventually becoming the head monologue writer earning 16 Emmy nominations and winning in 2007. He's also the author of The Astounding Misadventures of Rory Collins. It's been a pleasure to have him on the mat at Legacy in our early morning classes and to be able to sit down with him.Sponsored by TACFIT.com “The World's Smartest Workout” Açai Jungle Cafe “Your neighborhood Paradise” AcaiJungleCafe.com

Welcome to the Olink® Proteomics in Proximity podcast!   Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore 3072, the platform utilized by the UK Biobank to measure ~3000 proteins in plasma: https://olink.com/products-services/explore/·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  Press release and news story from UK Biobank:https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/launch-of-world-s-most-significant-protein-study-set-to-usher-in-new-understanding-for-medicine https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/dataset-of-thousands-of-proteins-marks-landmark-step-for-research-into-human-health https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies News stories:Today Programme – Professor Rory Collins live on programme, timestamp 02:36:37   Times – ‘Game-changing' study of blood proteins will help fight disease Independent – World's largest proteins study ‘invaluable' for understanding disease – experts Daily Mail – How Alzheimer's could be diagnosed a DECADE earlier following huge study of blood proteins Mirror – New blood test reveals risk of developing different diseases in 'new frontier of science' Science – Seeking disease insights, UK Biobank launches largest study of human proteinsTechnology Networks – UK Biobank Launches Largest Proteomics Study for Disease Research Chemical and Engineering News – Pharma firms team up to study UK proteomics data  Links to referred episodes:  • Evan – Episode 20:     https://share.transistor.fm/s/f795811e    https://open.spotify.com/episode/6lv5GA8hZCgDvujlBltS9f?si=36a29e6cfa4b4fae     https://podcasts.apple.com/us/podcast/how-proteomics-is-shaping-pharma-strategies/id1645900688?i=1000635040581 • Chris – Episode 16:     https://share.transistor.fm/s/255ad207     https://open.spotify.com/episode/0oe0S6zI8cryUtgZTjGlRq?si=8a7b0323b1364b96     https://podcasts.apple.com/us/podcast/interview-about-the-uk-biobank-with-dr-christopher-whelan/id1645900688?i=1000622521524  Subscribe to the podcast on your favorite player or app:Apple Podcasts: https://apple.co/3T0YbSm   Spotify Podcasts: https://open.spotify.com/show/2sZ2wxO...   Google Podcasts: https://podcasts.google.com/feed/aHR0...   Amazon Music:

Hang out with Al Mega as he chats with the man behind a sci-fi revolution in a groundbreaking biopunk comic, that is currently live on Kickstarter, Rory Collins. Tune in to learn all about this awesome new epic project and more… Support the Project at: https://www.kickstarter.com/projects/arks/arks-proximan-1 Follow on Social at: X: @ClickyW // Instagram:@clickysproutwife Website: www.clickysproutwife.com Episode 356 in an unlimited series! Host: Al Mega Follow on: Twitter | Instagram | Facebook): @TheRealAlMega / @ComicCrusaders Make sure to Like/Share/Subscribe if you haven't yet: https://www.youtube.com/c/comiccrusadersworld Twitch: https://www.twitch.tv/comiccrusaders Visit the official Comic Crusaders Comic Book Shop: comiccrusaders.shop Visit the OFFICIAL Comic Crusaders Swag Shop at: comiccrusaders.us Main Site: https://www.comiccrusaders.com/​​​​ Sister Site: http://www.undercovercapes.com​​​​ Pick up official Undercover Capes Podcast Network merchandise exclusively on RedBubble.com: bit.ly/UCPNMerch

This week, we're re-sharing one of our favorite episodes from the early days of The Genetics Podcast - one that many newer listeners may not have heard! Tune in as Professor Sir Rory Collins, Founder and Chief Executive of the UK Biobank, talks to us about the origins and evolution of this world-changing project that has catalysed a wave of new discoveries by levelling the playing field in data access. In this inspiring conversation, Professor Sir Rory Collins describes the ‘'If you build it, they will come get it” attitude of the UK Biobank. He believes that the pioneering and collaborative nature of UK Biobank means that the biggest impacts are yet to come. The conversation finishes with details on their COVID-19 work (as of 2020), which involved members from the original 500,000 strong UK Biobank cohort, as well as family members of these participants.

The incredible Brian Kiley is back this week as we share Part 2 of his great conversation with Mark and Lowell. Brian is one of the best and most well-respected TV comedy writers around. He's an Emmy award winner, and has written two fantastic books, "The Astounding Misadventures of Rory Collins" and "Maybe Kevin." This week Brian shares more insights into his experiences writing for both Conan and Ellen, how he crafts a comedy set, and his impressive regimen for being such a productive person. If you haven't already heard the first part, be sure to check out our past episodes to hear the first half of their conversation. If you're in the LA area on September 18 be sure to join Mark and Lowell for a live taping of the podcast at the world famous Hollywood Improv on Melrose! You can buy tickets here!Be sure to check out Mark's books:Available November 8, 2022."Why Not: Lessons on Comedy, Courage, and Chutzpah."Click on these links to buy:AmazonBarnes & NobleBooks-A-MillionBookshop.orgAnd read great road stories from some of the best comedians of our generation in Mark's first book  "I Killed: True Stories of the Road from America's Top Comics" available now!Please follow “You Don't Know Schiff” so you don't miss out on any exciting episodes. Click here to subscribe in Apple Podcasts (and please leave us 5 stars and a positive review - your support means the world to us and it helps us get discovered by new listeners):Your hosts:markschiff.comTwitter: @markschiffInstagram: markschiff1 Lowell BenjaminTwitter: @lowellcbenjaminInstagram: @lowellcbenjamin

Dawn and guest, Brian Kiley, were backstage at a comedy show when they first realized their shared love for History. In this episode, the two get to really let their nerd-flag fly and take turns sharing their favorite LOL moments from a wide variety of people, places and timelines. Prepare to feel (comparatively) less stupid in this episode devoted to History's Great Mistakes:00:04:40 - Before we dig deep in annals of history, we learn about Brian Kiley. How he first came to comedy, his Emmy nominations and wins for Conan O'Brien and Ellen - and how one prepares to make a 'last minute' appearance on Letterman. 00:10:43 - In addition to being a comedy writer, Brian Kiley is also a fiction-writer with two novels: The Astounding Misadventures of Rory Collins and Maybe Kevin.00:16:11 - Dawn finds herself in "nerd Paradise" as they prepare to jump in and swim around in the HILF of Great Mistakes.00:18:17 - Brian kicks things off with a hilarious and are-you-kidding-me nugget from our friends, the Pilgrims, and a certain 7' Native American. 00:20:54 - Dawn tells the story of The Children's Crusade - a tragically face-palming blip in the holy wars of Middle Ages in which a 12 year-old boy led over 30,000 children, on foot, across Europe to reclaim Jerusalem by slaying the enemy with their innocence... I know, right? 00:25:38 - It's Brian's turn and he brings us a moment featured in the movie THE RIGHT STUFF, in which astronaut John Glenn is temporarily mesmerized by brilliant otherworld particles in space... that turned out to be anything but. 00:27:33 - Dawn illustrates the ridiculous story of TULIP MANIA, when the Netherlands found themselves in the midst of the first economic bubble... but it was so pretty!BREAK00:33:22 - Before we jump back in, Dawn asks Brian if there is a comedian he can trace back to the origin of his interest in comedy, and he can:  Dick Gregory. 00:35:13 - Brian delivers the next LOL-HILF on his list, the hilarious story of the first hot-air ballon in France and the bizarre and yet totally predictable way that the people who see it react. 00:38:27 - In a one-two punch, Brian then tells the story of bright, yet unfortunate President Jimmy Carter and why his 2nd term seemed doomed to failure from the launch. 00:43:13 - It's Dawn's turn with a HILF of the worst building in London 'The Fryscraper' - and good/bad news - you can visit it to this day... and if you do, PLEASE SEND VIDEO. 00:48:57 - Brian was with his son in DC when he saw a misprinted headline from 1976 that suggested that two of the oldest, whitest, straightest guys in American politics just made-out in New Hampshire.00:52:00 - Wait til you hear what attempted presidential assassin, Squeaky Fromme, said as Gerald Ford's security took her down. 00:55:50 - Before I let him go, Brian delivers one more nugget about a presidential pet that would have been a welcome guest on HILF... if not a host. ---THANK YOU so much for listening. Please subscribe, share, rate & review us!LIVE RECORDING - May 26th, 2022 at The Glendale Reading Room in Glendale, CaliforniaNEXT EPISODE - EP17: Joan of Arc with Lauren Prichard. 

Theory and Practice speaks with Professor Sir Rory Collins, Head of Nuffield Department of Population Health at Oxford University and BHF (British Heart Foundation) Professor of Medicine and Epidemiology. Professor Collins is also Principal Investigator and Chief Executive of the UK Biobank.Relevant links:- Sir Rory Collins- Oxford University- British Heart Foundation- UK Biobank

Professor Sir Rory Collins, Founder and Chief Executive of the UK Biobank, talks to us this week about the origins of this world-changing project that has catalysed a wave of new discoveries in large part by levelling playing field in data access. In this inspiring conversation Professor Sir Rory Collins describes the 'if you build it, they will come' attitude of the UKBiobank, and how he believes the biggest impact from the UKBiobank is still to come. The conversation finishes with details on their COVID-19 work, which has involved not just members from the original 500,000 strong UKBiobank cohort, but also family members of these participants.

Professor Sir Rory Collins, Founder and Chief Executive of the UK Biobank, talks to us this week about the origins of this world-changing project that has catalysed a wave of new discoveries in large part by levelling playing field in data access. In this inspiring conversation Professor Sir Rory Collins describes the 'if you build it, they will come' attitude of the UKBiobank, and how he believes the biggest impact from the UKBiobank is still to come. The conversation finishes with details on their COVID-19 work, which has involved not just members from the original 500,000 strong UKBiobank cohort, but also family members of these participants.

Discussions of social determinants of health center on social programs as if they are equally available to everyone. The truth is, access to healthcare and social services is based on a punitive model that intentionally limits availability. So that’s what I dive into in this episode – here are the resources I mention: $1,000 a Month, No Strings Attached For Trans Women Silicone Pumping Can Be a Blessing and a Curse UK Biobank Requires Earth’s Geneticists to Cooperate, Not Compete Highlights include: 3:42 – “’Pumping’ refers to a kind of underground plastic surgery. Pumping is often turned to when licensed medicine isn’t accessible — typically because of a combination of social, financial and discriminatory barriers in health care.” Source: For Trans Women Silicone Pumping Can Be a Blessing and a Curse 5:30 – “Being able to pass as cisgender can, in some cases, be a matter of life and death.” Source: For Trans Women Silicone Pumping Can Be a Blessing and a Curse 5:54 – “Society defines who is worthy of health care, who is worthy of culturally competent care, who is worthy of even having access to health insurance,” Ruby Corado says. “And if you conform to [those] standards … then your privilege is that you can go to a doctor and get treated.” Source: For Trans Women Silicone Pumping Can Be a Blessing and a Curse 6:15 – JM: “It’s just pure luck whether we fall into a group where we get access to care or not.” 7:20 – JM: “We decide that some people are worth more and some people aren’t. It’s not random – it’s based on one group saying they want all the goodies and leaving all the other groups to scramble.” 10:03 – JM: “These judgments are more about the people making them than about the people receiving them.” 10:10 – “A nonprofit organization was looking to give 20 African American single mothers living in public housing $1,000 each month for a year. They’d be able to use the money in any way they pleased. … For decades, Republicans and Democrats alike have tried to push families out of poverty by adding restrictions to government welfare programs. There were work mandates, time limits, benefit caps — rules aimed at pointing families toward what the government thinks are good choices. Now, there is increasing interest in trying out the reverse.” Source: $1,000 a Month, No Strings Attached 11:30 – JM: “Think about how you would like it if someone tried to tell you how to spend your money. Or tried to tell you whether you were worth having a place to live. Think about how punitive our entire social welfare approach is. It’s all about ‘Are you worthy?’ of whatever the benefit is – and the benefit is so meager.” 12:07 – JM: “Hierarchies want the top to flourish and everybody else not to.” 13:25 – ““At the end of six months, none of the women reported using an emergency lender. Nearly all said they had enough money to buy school supplies, when fewer than half had said that before. They reported cooking more balanced meals, visiting the doctor and attending church more often. … ‘The beauty of all of this has just been how folks are light,’ Nyandoro said. ‘They aren’t walking around with the heaviness of life that, unfortunately, so many times low-income folks have to carry.’” Source: $1,000 a Month, No Strings Attached 14:43 – JM: “What if, we every time we wanted to add restrictions, we considered removing them, instead?” 16:09 – UK Biobank Chief Executive Dr. Rory Collins says, “The idea is to democratize research so scientists who might struggle to get funding and other resources can also make important contributions, using this dataset.” Source: UK Biobank Requires Earth’s Geneticists to Cooperate, Not Compete 16:25 – “(UK Biobank Chief scientist Dr. Cathie Sudlow) expects collaboration, rather than traditional competition, will be what really drives medical science forward.” Source: UK Biobank Requires Earth’s Geneticists to Cooperate, Not Compete 18:28 – JM: “How much of our society would be able to flourish if we stopped the judgment and stopped the restrictions and said, ‘What if we just gave you what you needed?'” 20:30 – JM: “It’s about making sure that women never feel adequate. And the result is that there is a huge amount of emotional energy that, instead of going to something we want, winds up going to this impossible and unnecessary task of changing our physical form.” 21:15 – JM: “What if we just had freedom to be beautiful the way we are?” 21:54 – JM: “What if we shook off all this baggage that we have been given that says we’re not worthy of even the most basic things, like being considered attractive or having a place to live or having food or being worthy of being listened to.” 23:27 – JM: “There is a difference between setting a boundary on something that has happened and is not being respectful of the gift that you’re giving and just restricting everything so that you’re not even allowing the other person to have the life that they deserve.” Leading with Health is the podcast where women dive into societal change through the lens of healthcare. Host Jennifer Michelle has a Master’s in Public Health and Epidemiology and is a certified EMT. As President of Michelle Marketing Strategies, Jennifer specializes in healthcare marketing. Jennifer is available to speak at conferences and also provides free marketing consultations. Contact her here.

In this episode of the podcast, hosted by Solange, Chris Bimson, Rory Collins, and Jorge Gueorguiev Garcia discuss The Craftsman's Oath by Robert C. Martin, also known as Uncle Bob Martin. Photo: Prairie Dog by DigiPD is licensed under CC0Music: "Sweeter Vermouth" by Kevin MacLeod is licensed under CC-BY 3.0

The women's and men's cross country teams both qualified for the NCAA Championships in the same year for the first time since 2012! Plus, we preview the basketball and swimming & diving seasons on the latest episode of the Bates Bobcast. Interviews this episode: 1:21 -- Bart Rust '22, Men's Cross Country (Male Bobcat of the Week) 8:52 -- Ayden Eickhoff '19, Women's Cross Country (Female Bobcat of the Week) 14:14 -- Alison Montgomery, Women's Basketball, Head Coach 22:01 -- Jon Furbush '05, Men's Basketball, Head Coach 28:42 -- Associate Head Coach Vanessa Williamson '05, Captains Catherine Mullen '19 and Rory Collins '19, Swimming and Diving

This podcast is an interview with Brian Kiley who is the author of, "The Astounding Misadventures of Rory Collins." Brian has been a staff writer for Conan O’Brien for 23 years and been nominated for 16 Emmy Awards one of which he won in 2007. He has appeared numerous times on the David Letterman show, Late Night with Conan and four times on the Tonight Show.

Emmy Award-winning writer Brian Kiley joins Nancy to discuss his early career from stand-up comedy and Late Night with Conan O’Brien, to his latest novel The Astounding Misadventures of Rory Collins. Read more in Nancy’s online column Showbiz Analysis for Parade Magazine.

Rory Collins discusses his Review of the evidence from randomised studies concerning the efficacy and safety of statins.

Brian Kiley is a stand-up, writer for Conan, and author of the book The Astounding Misadventures of Rory Collins.  Somehow, we haven't covered this album since our first three episodes, so it was definitely time for a revisit.  We sat down … Continue reading →

[intro music]   Hello, and welcome to Episode Twenty-two of Multiple Sclerosis Discovery, the podcast of the MS Discovery Forum. I’m your host, Dan Keller.   This week’s podcast features an interview with Dr. Paul Matthews about the Optimize project in the United Kingdom. But to begin, here’s a brief summary of some of the latest developments on the MS Discovery Forum at msdiscovery.org.   Some good news came from the pharmaceutical company Genzyme. On November 14th at 9 pm Eastern time, the FDA approved the drug alemtuzumab – trade name Lemtrada – for relapsing forms of MS. The FDA previously rejected the drug in 2013 due to concerns about study design and side effects. There is still some concern over safety, though, so the company is releasing it to only a limited number of patients. The prescription will also come with a host of other drugs to protect against harmful side effects. Researchers aren’t quite sure how the drug works, but it appears to target monocytes, T cells, and B cells.   Researchers announced a new mouse model for fatigue at the 2014 Society for Neuroscience meeting in Washington, D.C. The model works by enhancing expression of the pro-inflammatory cytokine, interleukin-1-beta. The model caused mice to reduce physical activity, without showing other signs of illness such as fever or anhedonia. Middle-aged and aged female mice were most affected by the treatment, whereas young mice showed no difference in signs of fatigue. The model gives credence to the idea that fatigue is not produced from dysfunction in the arousal system, but rather is a result of inflammation. The researchers said that they hoped the model will help illuminate the neurobiology of fatigue, the most common and debilitating symptom of MS.   If you would like to keep up with all things MSDF, please consider subscribing to our weekly newsletter. We keep our newsletter up-to-date with all of our news stories, blogs, and items from our professional and research resource sections. We’re also on Twitter; follow us at msdforum. And on Facebook, you can like us at facebook.com/ms discovery forum.   [transition music]   Now to the interview. Professor Paul Matthews is at Imperial College London in brain sciences. Last week he talked with MSDF about imaging in MS. This week we’re discussing his involvement in a UK-based project intended to optimize and personalize MS treatment.   Interviewer – Dan Keller Welcome, Professor Matthews. You’re participating in the Optimize project in the UK. Can you tell me about that?   Interviewee – Paul Matthews Well, thanks, Dan. Optimize has been an exciting journey and we’re still at the early stages, but let me tell you a little bit about it. Over three years ago, a number of us got together to discuss what the barriers to development of stratified or personalized medicine for multiple sclerosis was. We all recognized what the potential could be if we could really figure out how to target medicines to responders, we would have a way of most appropriately staging the introduction of different medicines across patient populations, not exposing people who didn’t need them to drugs of higher risk and insuring that those who did need them got them early. This is a particular problem in the United Kingdom where there is a much more formal process for progressing from first-line DMTs to more powerful agents. And, in fact, there’s also – dare I say it – I mean, a frank therapeutic nihilism and a surprisingly small number of MS patients receive treatment because of the perceived lack of benefit to many of these first-line therapies.   Now how to change this. I think what we realized is that we need to have much more granular data on the characteristics of patients being treated and how they fared after their treatment over the long-term. The data provided within the usual clinical context is not only limited, but it ends up being rather patchy over time. In order to enable that, we needed tools that would both collect data and incentivize collection of complete data of high quality. Now a note about this. We all know how to do this within the context of clinical trials, but it’s hugely expensive; it’s expensive because there are multiple people always involved to crosscheck that the data is completely acquired in each paper, and secondarily, there are audit procedures in place in retrospect to insure that this is being done. This really isn’t feasible in routine clinical practice.   A colleague of mine, Rory Collins, who has specialized in setting up very large-scale clinical trials in areas like China and India, has shown how very simple electronic tools can help both insure that data is acquired completely and that there is an electronic audit trail to follow-up on data that isn’t. What they showed is that by creating simple electronic questionnaires that wouldn’t let the questionnaire be closed unless data of an appropriate type was entered in the field, and then automatically interrogating the data for quality from center to center and following up where there were potential lapses, one could begin to incentivize acquisition of the right data and actually make it flow faster.   So how could we make this happen within the MS space in the UK? Well, what we realized is that the toolkits were all there. The EU IMI program already has funded my colleague, Yike Guo, who’s head of the Imperial College Data Science Institute, to create a tool built around a platform called eTRIKS. This is a data management environment that allows links to apps or iPads or any other peripheral electronic tool for very powerful distributed data capture. We then, in gathering together a number of stakeholder meetings which involved people with MS, the MS societies, a number of industry representatives, and what I’m really pleased to say is leads from fully 18 of the major MS centers across the United Kingdom pretty much ringing the country, together created the vision of building such an electronic tool, distributing the types of input devices across the different centers, and beginning to create a database that could be held centrally or in a distributed fashion using all the new tricks of modern IT.   The first thing is acquiring the data, the second is doing useful with it. The second thing that’s rather neat about the eTRIKS platform is that we have shown how it can be built to allow different levels of access, so that there can be access by high-level users who get to see the whole dataset, but also by specialized users who might want to see only a part of it – like a doctor interrogating it for his or her patient – or, importantly, a person with MS interrogating it to see how the data that they have entered stands relative to that that’s entered across the country by all patients; it allows people with MS to begin to gauge how they’re doing relative to others with their disease.   Now, I think the latter point is worth building on, because I think all of us have been hugely impressed by the power of sites like Patients Like Me to engage people with the disease in the dialog about their disease and make them full participants in capturing data information. With this kind of distributed data platform where doctors and people with MS can enter data whenever and wherever they are to a central database which can organize it and allow it then to be interrogated as needed, means that we can begin to think about asking patients to enter data on the fly from home. Why is this important? Well, this actually completely transforms the way in which we understand the disease, it really gives us a much deeper sense of the patient experience. Rather than sampling a patient once every month or once every six months, we can actually capture how they’re doing through a day. And if we add to this some extra sensor technologies – say, for example, about movement – we can literally do this from moment to moment.   So the vision thus is that if we can use these modern IT tools to capture data from distributed sources – from doctors using iPads, from patients using apps, from sensors that people with MS wear – we can capture data in a central resource that can be distributed to those for the purposes that they need it in near real-time, and in turn provide a common environment for its analysis. I think it’s exciting. Now we’re at the early stages, the basic tools have been designed, we’re starting to build the sensor technology. And our genuine hope is with the completion of the first set of agreements with one of the companies who’s been the first to really take a plunge with us, we’re going to be able to create a beta form of the tool in 6-9 months.   Now before closing, I do want to add one thing. This is an exciting vision but the notion of building a database is hardly a new one and many people have had it. There is something that’s special about this vision and it’s the thing that I’m most proud of that’s come together from all of these stakeholders. It’s the vision of creating a database that will be an open database; open to all researchers once it’s built, not held privately by those who built it. And I think this is what could become a game-changer. Moreover, we see that the tools that we’re building in order to create this – the IT tools, the distributed apps, and so on – are tools that the community should own and should be able to improve on. So our intention is fully, as this program develops, to release a software for open-access use as well as the data. Our hope is that even if this doesn’t provide the solution of the future, it will begin to incentivize this kind of practice where we all share this important data to work together to find solutions to this disease.   MSDF Besides collecting MS-specific data, will it also look at general health and comorbidities to see how that affects outcomes?   Dr. Matthews No. That’s a really good question. Like so many doctors now, we’re very much focused on the progressive forms of the disease. Our belief is that comorbidities make major contributions to this, and that by influencing these comorbidities we may have the biggest short-term impact on our patients’ lives. So one of the advantages of a big data capture tool is that we can capture data on all of the other disorders that afflict people with MS, as well, and begin with, again, greater granularity because of contributions from people with as well as their doctors to look at this in ways that wonderful databases like NARCOMS haven’t been able to do. This is an important task for the future and one that we really want to grasp. We’re hoping with further funding to be able to link this to bioresources, as well, and the ability to access a patient’s fluid samples for Omics analyses certainly can add greatly to this.   MSDF Very good, I appreciate it.   Dr. Matthews You’re welcome, Dan, it’s been good speaking to you.   [transition music]   Thank you for listening to Episode Twenty-two of Multiple Sclerosis Discovery. This podcast was produced by the MS Discovery Forum, MSDF, the premier source of independent news and information on MS research. MSDF’s executive editor is Robert Finn. Msdiscovery.org is part of the non-profit Accelerated Cure Project for Multiple Sclerosis. Robert McBurney is our President and CEO, and Hollie Schmidt is vice president of scientific operations.   Msdiscovery.org aims to focus attention on what is known and not yet known about the causes of MS and related conditions, their pathological mechanisms, and potential ways to intervene. By communicating this information in a way that builds bridges among different disciplines, we hope to open new routes toward significant clinical advances.   We’re interested in your opinions. Please join the discussion on one of our online forums or send comments, criticisms, and suggestions to editor@msdiscovery.org.    [outro music]  

Keith Fox, president of the British Cardiovascular Society, and Rory Collins, co-director of the University of Oxford's Clinical Trial Service Unit and Epidemiological Studies Unit, discuss the safety of statins, and how clever prescribing can overcome worries about myopathy. Also this week, Tony Delamothe, BMJ deputy editor, explains why the sudden interest in atrial fibrillation is making him queasy.

Where are we now with changing cholesterol levels to reduce cardiovascular disease risk? Keith Fox (British Cardiovascular Society president) asks Rory Collins (professor of Medicine and Epidemiology and co-director of the Clinical Trial Service, Nuffield Department of Clinical Medicine, University of Oxford).Professor Collins talks about the evidence behind altering high- and low-density lipoproteins, why the issue of myopathy has been overstated, and our best treatment options now and for the future.See also:Webcasts from all the sessions at the British Cardiovascular Society Conference 2012 http://bit.ly/ZMGmUE